MedTrace Logo

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

NCT00131027 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2008-11-14

No results posted yet for this study

Summary

The purpose of this study is to investigate the clinical efficacy of high-dose methotrexate consolidation therapy for adult patients with BCR-ABL-negative ALL.

Conditions

  • Lymphoblastic Leukemia, Acute

Interventions

DRUG

Cyclophosphamide

DRUG

Daunorubicin

DRUG

Vincristine

DRUG

Prednisolone

DRUG

L-asparaginase

DRUG

Cytarabine

DRUG

Etoposide

DRUG

Dexamethasone

DRUG

Methotrexate

3 g/sqm (high dose)

DRUG

Mercaptopurine

DRUG

Doxorubicin

DRUG

Methotrexate

0.5 g/sqm (intermediate dose)

Sponsors & Collaborators

  • Japan Adult Leukemia Study Group

    lead OTHER

Principal Investigators

  • Fumihiko Hayakawa, MD · Nagoya University

  • Tomoki Naoe, MD · Nagoya University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2011-03-31
Completion
2011-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00131027 on ClinicalTrials.gov